Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial

Mohamed Farag, Diana A Gorog

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


ABSTRACT  Vitamin K antagonists (VKAs) have traditionally been the standard of care for the thromboprophylactic anticoagulation of patients with nonvalvular atrial fibrillation (NVAF) undergoing cardioversion. X-VeRT was the first prospective trial to explore the safety and efficacy of one of the non-VKA oral anticoagulants, rivaroxaban, compared with dose-adjusted VKA as thromboprophylaxis in patients with NVAF scheduled to undergo cardioversion. The protocol allowed either early (1-5 days) or delayed (3-8 weeks) cardioversion to be performed. Rivaroxaban use (20 mg once daily or 15 mg if creatinine clearance was 30-49 ml/min) was associated with a similar incidence of adverse cardiovascular events and bleeding as VKA use; however, rivaroxaban significantly reduced the time to cardioversion in those undergoing delayed cardioversion. Thus, rivaroxaban is a safe alternative to VKAs for thromboprophylaxis in patients with NVAF undergoing elective cardioversion.

Original languageEnglish
Pages (from-to)147-51
Number of pages5
JournalFuture cardiology
Issue number2
Publication statusPublished - 11 Mar 2015


  • Atrial Fibrillation
  • Drug Administration Schedule
  • Electric Countershock
  • Factor Xa Inhibitors
  • Humans
  • Rivaroxaban
  • Thromboembolism
  • Treatment Outcome
  • Journal Article
  • Multicenter Study
  • Randomized Controlled Trial


Dive into the research topics of 'Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial'. Together they form a unique fingerprint.

Cite this